Your browser doesn't support javascript.
loading
[Biological treatment in dermatology--psoriasis]. / Biologická lécba v dermatologii--psoriáza.
Ettler, K.
Afiliación
  • Ettler K; Klinika nemocí kozních a pohlavních Lékarské fakulty UK a FN Hradec Králové. ettler@fnhk.cz
Vnitr Lek ; 57(9): 684-92, 2011 Sep.
Article en Cs | MEDLINE | ID: mdl-21957759
Psoriasis is a chronic, relapsing skin disease affecting 1-2% of the population. Genetically-determined autoimmune inflammation is initiated by an infection (e.g. streptococcal). T-lymphocytes, producing a number ofcytokines, mainly of the Th1 profile, including TNF alpha, play a key role. The role of Th17 and its interleukin IL-23 has recently been confirmed. It contains p40 protein, also a component of IL-12. TNF alpha and p40 blockade appear to be an effective biological treatment of severe lesional psoriasis. Further research and new drug development is to assure modern individualized treatment of psoriasis as well as other skin diseases.
Asunto(s)
Buscar en Google
Base de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Límite: Humans Idioma: Cs Revista: Vnitr Lek Año: 2011 Tipo del documento: Article
Buscar en Google
Base de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Límite: Humans Idioma: Cs Revista: Vnitr Lek Año: 2011 Tipo del documento: Article